Nieves Velez de Mendizabal

Nieves Velez de Mendizabal, PhD

Adjunct Assistant Research Professor of Medicine


In 2004, Nieves Velez de Mendizabal earned her degree as a Computer Engineer at the School of Informatics (University of the Basque Country, Spain). Two years later, she earned her M.Sc. degree in the same institution, focused on modeling biological systems and developing complex systems approaches in Biosciences. Nieves started her dissertation in the Department of Computer Science and Artificial Intelligence (University of the Basque Country, Spain) in collaboration with the Department of Neuroscience in the Center for Applied Medical Research (Pamplona, Spain) under the supervision of Dr. Pablo Villoslada. She received her PhD in October 2009. Her dissertation was mainly focused on applying System Dynamics framework to Biology. The models developed were applied to Immunology, specifically to HIV-1 infection dynamics and Multiple Sclerosis. The general aim of this kind of computational models is to shed some light about feasible mechanisms or processes that play a key role in the disease dynamic and its progression. At the end of her PhD, she started to work in population pharmacokinetics /pharmacodynamics (PK/PD) modeling in drug development using mainly NONMEM.In October 2009, Nieves started a first postdoc in pharmacokinetics and pharmacodynamic (PK/PD) at the Department of Pharmacy and Pharmaceutical Technology (University of Navarra, Spain) under the supervision of Iñaki F. Troconiz.In December 2011, she started her second postdoc at the Division of Clinical Pharmacology (Department of Medicine, Indiana University, US) under the Disease and Therapeutic Response Modeling Program funded by Eli Lilly pharmaceutical company and managed by Robert R. Bies. Her work is focused in translational research approaches conceptualizing biological systems and defining them mathematically. The use of these models is extremely useful for understanding biology and can be used for studying/predicting disease progression, as well as to generate highly feasible hypotheses. Specifically, PK/PD modeling mathematically/statistically describes the time course of effect intensity in response to administration of a drug dose, explaining/quantifying also the inter- and intra-subject variability. PK/PD modeling is currently a very important tool in drug development.Nieves recently became an academic contractor for Eli Lilly, and has earned an Assistant Research Professor position with Indiana University.


Clinical Pharmacology
R2 402 CPHR
Indianapolis, IN